兰索拉唑、阿莫西林二联疗法治疗幽门螺杆菌相关性慢性胃炎的疗效分析  

Analysis of curative effect of dual therapy with lansoprazole and amoxicillin for the treatment of Helicobacter pylori-associated chronic gastritis

作　　者：周静怡[1] ZHOU Jing-yi(Jinan Fifth People's Hospital,Jinan 250000,China)

机构地区：[1]济南市第五人民医院,250000

出　　处：《中国实用医药》2024年第8期111-113,共3页China Practical Medicine

摘　　要：目的 探讨对幽门螺杆菌(Hp)相关性慢性胃炎患者给予兰索拉唑、阿莫西林二联疗法治疗后获得的临床疗效。方法 120例Hp相关性慢性胃炎患者,以投掷硬币法分为参照组和研究组,每组60例。参照组患者施以兰索拉唑治疗,研究组患者施以兰索拉唑、阿莫西林二联疗法治疗。比较两组患者炎症因子水平[白细胞介素-8(IL-8)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]、Hp清除率、复发率以及不良反应(口苦、胃肠道反应、皮肤反应以及头晕)发生率。结果 治疗后,研究组患者IL-8、IL-6、TNF-α水平分别为(7.63±1.32)ng/L、(16.39±3.22)ng/L、(1.21±0.42)μg/ml,显著低于参照组的(9.39±1.55)ng/L、(34.52±13.49)ng/L、(1.85±0.53)μg/ml(P<0.05)。研究组患者Hp清除率98.33%(59/60)高于参照组的81.67%(49/60),复发率1.67%(1/60)低于参照组的13.33%(8/60)(P<0.05)。研究组患者不良反应发生率5.00%与参照组的3.33%比较,未呈现出明显差异(P>0.05)。结论 临床对Hp相关性慢性胃炎患者在治疗期间应用兰索拉唑+阿莫西林二联疗法,可将患者的炎症因子水平显著改善,同时将Hp清除率提高,将复发率降低,并且不会导致口苦、胃肠道反应、皮肤反应以及头晕等不良反应增加,疗效显著。Objective To explore the clinical efficacy of dual therapy with lansoprazole and amoxicillin for the treatment of patients with Helicobacter pylori(Hp)-associated chronic gastritis.Methods 120 patients with Hp-associated chronic gastritis were divided into a reference group and a study group by coin tossing method,with 60 cases in each group.The reference group was treated with lansoprazole,and the study group was treated with dual therapy with lansoprazole and amoxicillin.Comparison was made on levels of inflammatory factors[interleukin-8(IL-8),interleukin-6(IL-6),tumor cell necrosis factor-α(TNF-α)],Hp clearance rate,recurrence rate,and incidence of adverse reactions(bitter mouth,gastrointestinal reactions,skin reactions,and dizziness)between the two groups.Results After treatment,the levels of IL-8,IL-6 and TNF-αin the study group were(7.63±1.32)ng/L,(16.39±3.22)ng/L and(1.21±0.42)μg/ml,which were significantly lower than(9.39±1.55)ng/L,(34.52±13.49)ng/L and(1.85±0.53)μg/ml in the reference group(P<0.05).The study group had higher Hp clearance rate of 98.33%(59/60)than 81.67%(49/60)in the reference group,and lower recurrence rate of 1.67%(1/60)than 13.33%(8/60)in the reference group(P<0.05).The incidence of adverse reactions in the study group was 5.00%,which had no statistical significance compared with 3.33%in the reference group(P>0.05).Conclusion The clinical application of dual therapy with lansoprazole and amoxicillin has significant efficacy for patients with Hp-associated chronic gastritis,and can significantly improve the level of inflammatory factors in patients,increase the Hp clearance rate,reduce the recurrence rate,and will not lead to increased mouth pain,gastrointestinal reactions,skin reactions and dizziness.

关 键 词：兰索拉唑 阿莫西林 二联疗法 幽门螺杆菌 相关性慢性胃炎 应用效果 

分 类 号：R573.3[医药卫生—消化系统]